risvutatug rezetecan   Click here for help

GtoPdb Ligand ID: 14693

Synonyms: GSK'227 | GSK5764227 | HS-20093 | Ris-Rez
Compound class: Antibody
Comment: Risvutatug rezetecan (GSK5764227, formerly HS-20093; Ris-Rez) is an antibody-drug congugate that targets a camptothecin derived topoisomerase I inhibitor to (tumour) cells expressing CD276 (B7-H3) [2-3,5]. Peptide sequences for risvutatug's heavy and light chains are claimed in Hansoh patent US10899837B2, and these form the antibody named h1702 therein [4].
Click here for help
No information available.
Summary of Clinical Use Click here for help
Risvutatug rezetecan was progressed to clinical trials to evaluate safety and efficacy as a treatment for advanced solid tumours. It was granted orphan drug designation in Japan in March 2026, to allow treatment of small-cell lung cancer. This decision was based on supportive evidence from the phase I ARTEMIS-001 clinical trial [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05276609 ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors Phase 1 Interventional Hansoh BioMedical R&D Company The ARTEMIS-001 trial 1
NCT06498479 ARTEMIS-008:HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer Phase 3 Interventional Hansoh BioMedical R&D Company The ARTEMIS-008 trial
NCT06671379 A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC Phase 3 Interventional Suzhou Suncadia Biopharmaceuticals Co., Ltd. The HERON-Lung01 study